Company Update

Hindustan Biosciences has announced the publication of its financial results for the quarter ended June 30, 2026. The company reported zero revenue from operations and incurred total expenses of 0.11 Cr, leading to a net loss of 0.11 Cr for the period.

The Board of Directors approved these unaudited results, which provide shareholders an update on the company's financial performance within its pharmaceutical trading segment.

These results are accessible on the company's website.